Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 10,000 shares at $16.42 ($164K) on 2025-04-17, disclosed to the SEC on 2025-04-21.
Scheduled sale ($164k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.42 | 5,000 | $82K | 50.0% |
| 2 | $16.42 | 5,000 | $82K | 50.0% |
| Total | $16.42 avg | 10,000 | $164K | 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |